Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?

Saltarella I, Frassanito MA, Lamanuzzi A, Brevi A, Leone P, Desantis V, Di Marzo L, Bellone M, Derudas D, Ribatti D, Chiaramonte R, Palano MT, Neri A, Mariggiò MA, Fumarulo R, Dammacco F, Racanelli V, Vacca A, Ria R.

Neoplasia. 2019 Jan;21(1):93-105. doi: 10.1016/j.neo.2018.10.011. Epub 2018 Dec 5.

2.

Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.

Calcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, Kumar S, Garbitt VM, Sharik ME, Henderson KJ, Tonon G, Tomura M, Miwa Y, Esplugues E, Flavell RA, Huber S, Canducci F, Rajkumar VS, Bergsagel PL, Bellone M.

Nat Commun. 2018 Dec 3;9(1):4832. doi: 10.1038/s41467-018-07305-8.

3.

Propofol vs. inhalational agents to maintain general anaesthesia in ambulatory and in-patient surgery: a systematic review and meta-analysis.

Schraag S, Pradelli L, Alsaleh AJO, Bellone M, Ghetti G, Chung TL, Westphal M, Rehberg S.

BMC Anesthesiol. 2018 Nov 8;18(1):162. doi: 10.1186/s12871-018-0632-3.

4.

Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.

Elia AR, Caputo S, Bellone M.

Front Immunol. 2018 Jul 31;9:1786. doi: 10.3389/fimmu.2018.01786. eCollection 2018. Review.

5.

Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression.

Cortesi F, Delfanti G, Grilli A, Calcinotto A, Gorini F, Pucci F, Lucianò R, Grioni M, Recchia A, Benigni F, Briganti A, Salonia A, De Palma M, Bicciato S, Doglioni C, Bellone M, Casorati G, Dellabona P.

Cell Rep. 2018 Mar 13;22(11):3006-3020. doi: 10.1016/j.celrep.2018.02.058.

6.

Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.

Elia AR, Grioni M, Basso V, Curnis F, Freschi M, Corti A, Mondino A, Bellone M.

Clin Cancer Res. 2018 May 1;24(9):2171-2181. doi: 10.1158/1078-0432.CCR-17-2210. Epub 2018 Feb 28.

7.

Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization.

Sorrentino C, Ciummo SL, Cipollone G, Caputo S, Bellone M, Di Carlo E.

Cancer Res. 2018 May 15;78(10):2654-2668. doi: 10.1158/0008-5472.CAN-17-3117. Epub 2018 Feb 27.

8.

Innovative Therapy, Monoclonal Antibodies and Beyond.

Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M.

Cytokine Growth Factor Rev. 2017 Dec;38:1-9. doi: 10.1016/j.cytogfr.2017.10.002. Epub 2017 Oct 5.

PMID:
29029813
9.

Osteopontin and the immune system: another brick in the wall.

Caputo S, Bellone M.

Cell Mol Immunol. 2018 Apr;15(4):405-407. doi: 10.1038/cmi.2017.94. Epub 2017 Oct 2. No abstract available.

10.

Pharmacoeconomics of parenteral nutrition in surgical and critically ill patients receiving structured triglycerides in China.

Wu GH, Ehm A, Bellone M, Pradelli L.

Asia Pac J Clin Nutr. 2017;26(6):1021-1031. doi: 10.6133/apjcn.022017.04.

11.

PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer.

Petitprez F, Fossati N, Vano Y, Freschi M, Becht E, Lucianò R, Calderaro J, Guédet T, Lacroix L, Rancoita PMV, Montorsi F, Fridman WH, Sautès-Fridman C, Briganti A, Doglioni C, Bellone M.

Eur Urol Focus. 2019 Mar;5(2):192-196. doi: 10.1016/j.euf.2017.05.013. Epub 2017 Jun 21.

PMID:
28753812
12.

Fatty is not that bad: feeding short-chain fatty acids to restrain autoimmunity.

Brevi A, Bellone M.

Cell Mol Immunol. 2017 Jul 17. doi: 10.1038/cmi.2017.52. [Epub ahead of print] No abstract available.

13.

Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT).

Russo V, Amadori A, Bregni M, Calabrò L, Colombo MP, Di Nicola M, Ferrucci PF, Proietti E, Maio M, Bellone M.

Cytokine Growth Factor Rev. 2017 Aug;36:1-3. doi: 10.1016/j.cytogfr.2017.06.004. Epub 2017 Jun 16.

PMID:
28634022
14.

Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer.

Bellone M, Elia AR.

Cytokine Growth Factor Rev. 2017 Aug;36:17-24. doi: 10.1016/j.cytogfr.2017.06.002. Epub 2017 Jun 2. Review.

PMID:
28606732
15.

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.

Gorini F, Azzimonti L, Delfanti G, Scarfò L, Scielzo C, Bertilaccio MT, Ranghetti P, Gulino A, Doglioni C, Di Napoli A, Capri M, Franceschi C, Caligaris-Cappio F, Ghia P, Bellone M, Dellabona P, Casorati G, de Lalla C.

Blood. 2017 Jun 29;129(26):3440-3451. doi: 10.1182/blood-2016-11-751065. Epub 2017 May 2.

16.

Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.

Jachetti E, Rigoni A, Bongiovanni L, Arioli I, Botti L, Parenza M, Cancila V, Chiodoni C, Festinese F, Bellone M, Tardanico R, Tripodo C, Colombo MP.

Mol Cancer Ther. 2017 Feb;16(2):365-375. doi: 10.1158/1535-7163.MCT-16-0466. Epub 2016 Dec 15.

17.

T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.

Manzo T, Sturmheit T, Basso V, Petrozziello E, Hess Michelini R, Riba M, Freschi M, Elia AR, Grioni M, Curnis F, Protti MP, Schumacher TN, Debets R, Swartz MA, Corti A, Bellone M, Mondino A.

Cancer Res. 2017 Feb 1;77(3):658-671. doi: 10.1158/0008-5472.CAN-16-0725. Epub 2016 Nov 21.

18.

Long non-coding RNAs as novel therapeutic targets in cancer.

Lavorgna G, Vago R, Sarmini M, Montorsi F, Salonia A, Bellone M.

Pharmacol Res. 2016 Aug;110:131-138. doi: 10.1016/j.phrs.2016.05.018. Epub 2016 May 19. Review.

PMID:
27210721
19.

Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.

Bianco M, Gasparri AM, Colombo B, Curnis F, Girlanda S, Ponzoni M, Bertilaccio MT, Calcinotto A, Sacchi A, Ferrero E, Ferrarini M, Chesi M, Bergsagel PL, Bellone M, Tonon G, Ciceri F, Marcatti M, Caligaris-Cappio F, Corti A.

Cancer Res. 2016 Apr 1;76(7):1781-91. doi: 10.1158/0008-5472.CAN-15-1637. Epub 2016 Feb 11.

20.

Targeting vasculogenesis to prevent progression in multiple myeloma.

Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, Calcinotto A, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, Roccaro AM, Ghobrial IM.

Leukemia. 2016 May;30(5):1103-15. doi: 10.1038/leu.2016.3. Epub 2016 Feb 3.

PMID:
26859080
21.

Development of Ms Budget Manager: A Practical Tool to Assist Alternative Stakeholders At Multiple Decision Levels In The Forecast And Financial Management For Multiple Sclerosis (Ms).

Pradelli L, Bellone M, Zaniolo O.

Value Health. 2015 Nov;18(7):A765. doi: 10.1016/j.jval.2015.09.2509. Epub 2015 Oct 20. No abstract available.

22.

Cost-Effectiveness Analysis Of Neo-Adjuvant Pertuzumab Therapy In Women With Locally Advanced, Inflammatory, Or Early Her2-Positive Breast Cancer In Italy.

Pradelli L, Bellone M, Era S, Campagnoli E.

Value Health. 2015 Nov;18(7):A454. doi: 10.1016/j.jval.2015.09.1156. Epub 2015 Oct 20. No abstract available.

23.

Immunosuppression via Tenascin-C.

Bellone M, Caputo S, Jachetti E.

Oncoscience. 2015 Aug 21;2(8):667-8. eCollection 2015. No abstract available.

24.

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.

Calcinotto A, Ponzoni M, Ria R, Grioni M, Cattaneo E, Villa I, Sabrina Bertilaccio MT, Chesi M, Rubinacci A, Tonon G, Bergsagel PL, Vacca A, Bellone M.

Oncoimmunology. 2015 May 7;4(6):e1008850. eCollection 2015 Jun.

25.

A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.

Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C.

Oncoimmunology. 2014 Dec 21;3(11):e963406. eCollection 2014 Nov.

26.

Retrospective analysis of community hospital red blood cell recovery procedures: improved utilization needed for effectiveness.

Bellone M, Pham HP, Shaz BH, Shi PA.

Transfusion. 2015 Aug;55(8):1972-9. doi: 10.1111/trf.13062. Epub 2015 Apr 1.

PMID:
25827192
27.

Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation.

Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M, Piras IS, Restuccia U, Calcinotto A, Freschi M, Bachi A, Galli R, Bellone M.

Cancer Res. 2015 May 15;75(10):2095-108. doi: 10.1158/0008-5472.CAN-14-2346. Epub 2015 Mar 25.

28.

Cost Effectiveness Analysis Of Apixaban Versus Other Noacs For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients.

Pradelli L, Calandriello M, Di VR, Bellone M, Tubaro M.

Value Health. 2014 Nov;17(7):A487-8. doi: 10.1016/j.jval.2014.08.1432. Epub 2014 Oct 26. No abstract available.

29.

Pharmacoeconomic Assessment Of Apixaban Versus Standard Of Care For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients.

Pradelli L, Calandriello M, Di VR, Bellone M, Tubaro M.

Value Health. 2014 Nov;17(7):A486-7. doi: 10.1016/j.jval.2014.08.1427. Epub 2014 Oct 26. No abstract available.

30.

Budget Impact Analysis Of Apixaban Versus Other Noacs For The Prevention Of Stroke In Italian Non-Valvular Atrial Fibrillation Patients.

Pradelli L, Calandriello M, Di VR, Bellone M, Tubaro M.

Value Health. 2014 Nov;17(7):A479. doi: 10.1016/j.jval.2014.08.1383. Epub 2014 Oct 26. No abstract available.

31.

Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer.

Orfanelli U, Jachetti E, Chiacchiera F, Grioni M, Brambilla P, Briganti A, Freschi M, Martinelli-Boneschi F, Doglioni C, Montorsi F, Bellone M, Casari G, Pasini D, Lavorgna G.

Oncogene. 2015 Apr 16;34(16):2094-102. doi: 10.1038/onc.2014.144. Epub 2014 Jun 16.

PMID:
24931166
32.

IGH amplification in patients with B cell lymphoma unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt's lymphoma.

Bellone M, Zaslav AL, Ahmed T, Lee HL, Ma Y, Hu Y.

Biomark Res. 2014 May 9;2:9. doi: 10.1186/2050-7771-2-9. eCollection 2014.

33.
34.

Induction of T-cell memory by a dendritic cell vaccine: a computational model.

Pappalardo F, Pennisi M, Ricupito A, Topputo F, Bellone M.

Bioinformatics. 2014 Jul 1;30(13):1884-91. doi: 10.1093/bioinformatics/btu059. Epub 2014 Mar 6.

PMID:
24603984
35.

Tumor-targeting vaccination instructs graft-vs.-tumor immune responses.

Manzo T, Michelini RH, Sturmheit T, Basso V, Bellone M, Mondino A.

Oncoimmunology. 2013 Oct 1;2(10):e25996. Epub 2013 Sep 12.

36.

Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads.

Marcucci F, Bellone M, Caserta CA, Corti A.

Int J Cancer. 2014 Sep 15;135(6):1265-76. doi: 10.1002/ijc.28572. Epub 2013 Nov 13. Review.

37.

Boosting anticancer vaccines: Too much of a good thing?

Ricupito A, Grioni M, Calcinotto A, Bellone M.

Oncoimmunology. 2013 Jul 1;2(7):e25032. Epub 2013 May 16.

38.

Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes.

Bellone M, Calcinotto A.

Front Oncol. 2013 Sep 11;3:231. doi: 10.3389/fonc.2013.00231. Review.

39.

Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.

Mazzoleni S, Jachetti E, Morosini S, Grioni M, Piras IS, Pala M, Bulfone A, Freschi M, Bellone M, Galli R.

Stem Cells Transl Med. 2013 Sep;2(9):678-89. doi: 10.5966/sctm.2013-0041. Epub 2013 Jul 24.

40.

Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses.

Jachetti E, Mazzoleni S, Grioni M, Ricupito A, Brambillasca C, Generoso L, Calcinotto A, Freschi M, Mondino A, Galli R, Bellone M.

Oncoimmunology. 2013 May 1;2(5):e24520. Epub 2013 Apr 16.

41.

Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation.

Hess Michelini R, Manzo T, Sturmheit T, Basso V, Rocchi M, Freschi M, Listopad J, Blankenstein T, Bellone M, Mondino A.

Cancer Res. 2013 Aug 1;73(15):4641-52. doi: 10.1158/0008-5472.CAN-12-3464. Epub 2013 Jun 7.

42.

Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings.

Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, Bellone M.

Cancer Res. 2013 Jun 15;73(12):3545-54. doi: 10.1158/0008-5472.CAN-12-2449. Epub 2013 Mar 28.

43.

The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors.

Bellone M, Calcinotto A, Filipazzi P, De Milito A, Fais S, Rivoltini L.

Oncoimmunology. 2013 Jan 1;2(1):e22058.

44.

Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.

Marcucci F, Bellone M, Rumio C, Corti A.

MAbs. 2013 Jan-Feb;5(1):34-46. doi: 10.4161/mabs.22775. Epub 2012 Dec 4. Review.

45.

Pediatric T-cell prolymphocytic leukemia with an isolated 12(p13) deletion and aberrant CD117 expression.

Bellone M, Svensson AM, Zaslav AL, Spitzer S, Golightly M, Celiker M, Hu Y, Ma Y, Ahmed T.

Exp Hematol Oncol. 2012 Apr 18;1(1):7. doi: 10.1186/2162-3619-1-7.

46.

Won't you come on in? How to favor lymphocyte infiltration in tumors.

Bellone M, Calcinotto A, Corti A.

Oncoimmunology. 2012 Sep 1;1(6):986-988.

47.

Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer.

Bellone M, Rigamonti N.

Cancer Immunol Immunother. 2012 Dec;61(12):2377-8. doi: 10.1007/s00262-012-1310-9. Epub 2012 Jun 28. No abstract available.

PMID:
22740161
48.

Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.

Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, Cova A, Canese R, Jachetti E, Rossetti M, Huber V, Parmiani G, Generoso L, Santinami M, Borghi M, Fais S, Bellone M, Rivoltini L.

Cancer Res. 2012 Jun 1;72(11):2746-56. doi: 10.1158/0008-5472.CAN-11-1272. Epub 2012 May 16.

49.

Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.

Rigamonti N, Bellone M.

Cancer Immunol Immunother. 2012 Apr;61(4):453-68. doi: 10.1007/s00262-012-1216-6. Epub 2012 Feb 14. Review.

PMID:
22331081
50.

Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy.

Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, Corti A, Bellone M.

J Immunol. 2012 Mar 15;188(6):2687-94. doi: 10.4049/jimmunol.1101877. Epub 2012 Feb 8.

Supplemental Content

Loading ...
Support Center